行情

SUPN

SUPN

Supernus制药
NASDAQ

实时行情|Nasdaq Last Sale

29.65
+0.43
+1.47%
盘后: 29.30 -0.35 -1.18% 19:21 01/21 EST
开盘
29.00
昨收
29.22
最高
30.44
最低
29.00
成交量
56.75万
成交额
--
52周最高
34.50
52周最低
23.15
市值
15.77亿
市盈率(TTM)
19.67
分时
5日
1月
3月
1年
5年
HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...
Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics...
GuruFocus.com · 4天前
Advisors' Inner Circle Fund III Buys Washington Federal Inc, Supernus Pharmaceuticals Inc, ...
Investment company Advisors' Inner Circle Fund III (Current Portfolio) buys Washington Federal Inc, Supernus Pharmaceuticals Inc, Portland General Electric Co, First Foundation Inc, Atlantic Union Bankshares Corp, sells Steven Madden, Signet Jewelers, Oxfo...
GuruFocus.com · 2021/12/28 04:38
ICE Biotech index rejig: AUPH, AVXL among added; AMRS, GH among deleted
Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals
Seekingalpha · 2021/12/17 16:54
Inv Corp Small Cap Value 收购 Zuora Inc、Home BancShares Inc、Tegna Inc,出售 Zurn Water ...
GuruFocus News · 2021/12/08 21:38
Brief-Supernus 重新提交 Spn-830 阿扑吗啡输液装置的 NDA
reuters.com · 2021/12/08 13:51
Analysts Just Published A Bright New Outlook For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) shareholders will have a reason to smile today, with the analysts making...
Simply Wall St. · 2021/12/08 13:48
Supernus Pharma Reports Resubmission Of New Drug Application For SPN-830 Apomorphine Infusion Device
ernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its
Benzinga · 2021/12/08 13:31
Supernus Pharma resumed Buy at Jefferies citing Adamas acquisition
Jefferies has reinstated the coverage of Supernus Pharmaceuticals (SUPN +6.9%) with a Buy rating on the completion of the company’s $850M acquisition of Adamas Pharmaceuticals in November. With the closure of
Seekingalpha · 2021/12/01 15:59
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解SUPN最新的财务预测,通过SUPN每股收益,每股净资产,每股现金流等数据分析Supernus制药近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

25.00%强力推荐
50.00%买入
25.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测SUPN价格均价为36.50,最高价位44.00,最低价为30.00。
最高44.00
均价36.50
最低30.00
现价29.65
EPS
实际EPS
预期EPS
0.140.280.430.57
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 383
机构持股: 6,501.26万
持股比例: 122.25%
总股本: 5,318.08万
类型机构数股数
增持
75
287.04万
建仓
34
138.15万
减持
76
356.33万
平仓
32
36.94万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.92%
制药与医学研究
-1.11%
高管信息
Chairman/Independent Director
Charles Newhall
President/Chief Executive Officer/Secretary/Director
Jack Khattar
Chief Financial Officer/Senior Vice President
Timothy Dec
Senior Vice President/Chief Scientific Officer
Padmanabh Bhatt
Senior Vice President
Tami Martin
Senior Vice President
Frank Mottola
Senior Vice President
Jonathan Rubin
Independent Director
Carrolee Barlow
Independent Director
Frederick Hudson
暂无数据
SUPN 简况
Supernus Pharmaceuticals Inc是一家生物制药公司。该公司专注于开发和销售用于治疗中枢神经系统(CNS)疾病的产品。其多样化的神经科学产品包括治疗癫痫、偏头痛、帕金森病(PD)的活动不足、颈肌张力障碍和慢性流涎。其商业产品包括用于治疗癫痫的Trokendi XR(托吡酯)和Oxtellar XR(奥卡西平)。其APOKYN(盐酸阿扑吗啡注射液)是一种适用于急性、间歇性治疗晚期帕金森病(PD)患者活动不足的产品。其XADAGO(沙芬酰胺)是一种用于PD患者左旋多巴/卡比多巴辅助治疗的产品。其MYOBLOC(rimabotulinumtoxinB)是一种用于治疗成人颈部肌张力障碍和流涎的产品。其CNS候选产品管线包括SPN-812、SPN-817、SPN-820、SPN-830和MYOBLOC。

微牛提供Supernus Pharmaceuticals Inc(NASDAQ-SUPN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的SUPN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易SUPN股票基本功能。